Terumo’s acquisition of MicroVention allowed both companies to capitalize on their unique, proprietary technologies and facilitate additional focus on new technologies.
Founded in 1997, MicroVention has been focusing on endovascular treatment of neurovascular disease, which affects hundreds of thousands of patients worldwide, and it has consistently developed an innovative approach.
Headquartered in Tustin, California, MicroVention sells its products in over 60 countries around the world and has manufacturing facilities in Southern California and Costa Rica. It is now a company with more than 1,000 employees across the globe and posts consistent andcontinuing growth.
“MicroVention sets the standard of excellence in the neuroendovascular device industry and our unique collaboration with Terumo has allowed MicroVention to constantly develop new and innovative devices to complement our existing line of quality products,” said President and Chief Executive Officer Richard Cappetta.
Innovation, clinical relevance and customer focus have been MicroVention’s shared values with Terumo.
The two companies also continuously maintain key communications through project collaboration and an entrepreneurial culture that fosters team spirit and empowers all of their associates.
“As a Terumo affiliated company, we are committed to developing and manufacturing the highest quality products for our customers and patients. In addition, we expect every associate to be empowered in each position and to be proactive in ‘contributing to society through healthcare’.” Cappetta said.